The single-cell genomics industry has taken a significant step forward as ArgenTag, a company founded in Argentina during the COVID-19 pandemic, officially announced its partnership with PacBio. This collaboration integrates ArgenTag’s Single-Cell RNA Library Kit with PacBio’s Kinnex RNA kits, enabling researchers to conduct long-read isoform sequencing at single-cell resolution. The partnership aims to enhance access to advanced genomic technologies in South America, where such resources have been historically limited.
Established with a vision to fill the gap in single-cell instrument accessibility, ArgenTag focuses on long-read technologies, believing they will play a crucial role in the future of transcriptomics. The co-marketing agreement between the two companies not only confirms their compatibility but also simplifies the research process by eliminating the need for specialized capital equipment for cell partitioning.
The Importance of Long-Read Sequencing
The choice to prioritize long-read sequencing stems from the limitations of short-read technologies, which often fail to capture comprehensive genomic information. “When you do short reads, you’re not getting all the information,” explained Sofía Lavista Llanos, PhD, the director of process development at ArgenTag. She emphasized that short reads provide only a snapshot of the transcriptome, potentially missing critical data related to isoform diversity and gene regulation.
ArgenTag’s innovative workflow utilizes a portable, gravity-based microfluidic chip technology for cell partitioning and barcoding. The chip features microwells that allow for cell partitioning and contain beads carrying barcodes, facilitating multiplex long-read sequencing. This technology was first detailed in a paper published in Scientific Reports in May 2022, titled “Robust and scalable barcoding for massively parallel long-read sequencing.”
When combined with PacBio’s Kinnex kits and HiFi long-read sequencing, the resulting benchtop workflow provides researchers with a scalable solution for generating full-length, single-cell transcriptomic data. This advancement offers researchers the ability to explore complete isoform diversity, alternative splicing events, and gene fusions—elements often overlooked by short-read methods that focus primarily on the 3′ end of transcripts.
New Opportunities for Researchers
The partnership not only enhances technological capabilities but also opens new avenues for scientific research. Access to full-length isoform data at the single-cell level is poised to transform biomarker discovery, improve understanding of complex gene regulations, and facilitate the development of novel therapeutics. ArgenTag stands out as one of the few companies dedicated to providing solutions specifically designed for long-read sequencing, which enhances biological clarity beyond what is achievable with traditional short-read platforms.
In addition, ArgenTag is launching a Single-Cell Long-Read Research Grant Program aimed at supporting innovative or exploratory long-read single-cell projects. The application period for this grant opens on February 17, 2026, and closes on March 3, 2026, at 23:59 ET. More details, including eligibility criteria and application instructions, can be found on the ArgenTag website.
“Our mission at ArgenTag is to enable scientists to better understand health and disease with long-read single-cell sequencing solutions,” stated Leandro Ciappina, CEO of ArgenTag. “By joining PacBio Compatible, we are enabling more researchers to access high-resolution, long-read data. This compatibility empowers any lab to explore the full complexity of the transcriptome at single-cell resolution.”
This partnership marks a pivotal moment in the ongoing evolution of genomic research, particularly in regions that have faced challenges in accessing advanced technologies. As ArgenTag and PacBio work together, the impact of their collaboration may extend far beyond the laboratory, potentially influencing the future of medical diagnostics and therapies globally.
